TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Minimization of Surgical Site Infections for Pts Undergoing Colorectal Surgery
Brief Summary: This is a comparison, at this VA Hospital, of standard operating room management in colorectal surgery to a more rigid management using an additional five previously tested treatments to determine if this changes the rate of post operative wound infections.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Oxygen by mask | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Oxygen by mask | Intervention Type: OTHER; Name: Oxygen by mask; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Oxygen by mask; Assigned to Arm(s): 2
B: Arm Label: Oxygen therapy; Type: OTHER; Interventions: Other: Oxygen therapy | Arm Label: No oxygen therapy; Type: OTHER; Interventions: Other: No oxygen therapy | Intervention Type: OTHER; Name: Oxygen therapy; Assigned to Arm(s): Oxygen therapy | Intervention Type: OTHER; Name: No oxygen therapy; Assigned to Arm(s): No oxygen therapy
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard operating management | Intervention Type: PROCEDURE; Name: standard operating management; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental postoperative oxygen | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: supplemental postoperative oxygen; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-vaccinated, HIV-negative Infants
Brief Summary: This was a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity and efficacy of MVA85A/AERAS-485 in Bacillus Calmette-Guérin (BCG) vaccinated infants without tuberculosis or HIV infection. This study planned to enroll 2784 infants (126 to 182 days of age) who received study vaccine or control and were followed for 15 - 36 months. The study was conducted at a single site in South Africa.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Xpert MTB/RIF Ultra (Ultra) | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert MTB/RIF Ultra (Ultra); Assigned to Arm(s): Interventional
B: Intervention Type: OTHER; Name: Development of a diagnosis algorithm; Assigned to Arm(s): N/A
C: Arm Label: Urgent ART; Type: EXPERIMENTAL; Interventions: Other: Urgent ART | Arm Label: Early ART; Type: ACTIVE_COMPARATOR; Interventions: Other: Early ART | Intervention Type: OTHER; Name: Urgent ART; Assigned to Arm(s): Urgent ART | Intervention Type: OTHER; Name: Early ART; Assigned to Arm(s): Early ART
D: Arm Label: Investigational Vaccine; Type: EXPERIMENTAL; Interventions: Biological: MVA85A/AERAS-485 | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Candida Skin Test Antigen | Intervention Type: BIOLOGICAL; Name: MVA85A/AERAS-485; Assigned to Arm(s): Investigational Vaccine | Intervention Type: BIOLOGICAL; Name: Candida Skin Test Antigen; Assigned to Arm(s): Control Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-vaccinated, HIV-negative Infants
Brief Summary: This was a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity and efficacy of MVA85A/AERAS-485 in Bacillus Calmette-Guérin (BCG) vaccinated infants without tuberculosis or HIV infection. This study planned to enroll 2784 infants (126 to 182 days of age) who received study vaccine or control and were followed for 15 - 36 months. The study was conducted at a single site in South Africa.


Options:
A: Arm Label: Investigational Vaccine; Type: EXPERIMENTAL; Interventions: Biological: MVA85A/AERAS-485 | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Candida Skin Test Antigen | Intervention Type: BIOLOGICAL; Name: MVA85A/AERAS-485; Assigned to Arm(s): Investigational Vaccine | Intervention Type: BIOLOGICAL; Name: Candida Skin Test Antigen; Assigned to Arm(s): Control Group
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: MVA85A-IMX313 | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: MVA85A-IMX313 | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Biological: MVA85A | Intervention Type: BIOLOGICAL; Name: MVA85A-IMX313; Assigned to Arm(s): Group A, Group B | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): Group C
C: Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses
Brief Summary: The purpose of this study is to explore the benefits of "Exercising Together"-a partnered strength training program for married couples coping with prostate cancer- on the physical and emotional health of prostate cancer survivors and their spouse and on marital quality.


Options:
A: Arm Label: Arm I (strength training); Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Other: Questionnaire Administration | Arm Label: Arm II (tai chi); Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Other: Questionnaire Administration | Arm Label: Arm III (control); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise Intervention, Other: Questionnaire Administration | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Arm I (strength training) | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Arm II (tai chi) | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Arm III (control) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (strength training), Arm II (tai chi), Arm III (control)
B: Arm Label: Exercising Together; Type: EXPERIMENTAL; Interventions: Behavioral: Randomized Exercise Intervention | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Randomized Exercise Intervention | Intervention Type: BEHAVIORAL; Name: Randomized Exercise Intervention; Assigned to Arm(s): Exercising Together | Intervention Type: BEHAVIORAL; Name: Randomized Exercise Intervention; Assigned to Arm(s): Usual Care
C: Arm Label: Football; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Football | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Football; Assigned to Arm(s): Football
D: Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of Linagliptin (5 mg), Administered Orally Once Daily for at Least 52 Weeks in Type 2 Diabetic Patients in Combination With Basal Insulin Therapy
Brief Summary: The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.


Options:
A: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
B: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
C: Arm Label: Linagliptin; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin
D: Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of Linagliptin (5 mg), Administered Orally Once Daily for at Least 52 Weeks in Type 2 Diabetic Patients in Combination With Basal Insulin Therapy
Brief Summary: The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.


Options:
A: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2
C: Arm Label: Coronary Artery Bypass Graft; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Coronary Artery Bypass Graft | Arm Label: Percutaneous Coronary Intervention; Type: EXPERIMENTAL; Interventions: Device: Percutaneous Coronary Intervention | Intervention Type: PROCEDURE; Name: Coronary Artery Bypass Graft; Assigned to Arm(s): Coronary Artery Bypass Graft | Intervention Type: DEVICE; Name: Percutaneous Coronary Intervention; Assigned to Arm(s): Percutaneous Coronary Intervention
D: Arm Label: Linagliptin; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Arthralgia and Medication Adherence in Women With Early Stage Breast Cancer Taking Aromatase Inhibitors: The Breast Cancer Adjuvant Therapy (BCAT) Longitudinal Cohort Study.
Brief Summary: RATIONALE: Gathering information over time about joint pain and stiffness from postmenopausal women with early-stage breast cancer who are receiving aromatase inhibitors may help doctors plan treatment and help patients live more comfortably.

PURPOSE: This observational epidemiologic cohort is designed to study arthralgia, patient-reported outcomes, and medication adherence in postmenopausal women with early-stage breast cancer who are receiving aromatase inhibitors.


Options:
A: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Dietary Supplement: omega-3 fatty acid | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: omega-3 fatty acid; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
B: Arm Label: Arm I/Group A (Duloxetine then Placebo); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Arm Label: Arm II/Group B (Placebo then Duloxetine); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine)
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Questioners | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: STAR website | Intervention Type: BEHAVIORAL; Name: Questioners; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: STAR website; Assigned to Arm(s): B
D: Intervention Type: OTHER; Name: aromatase inhibition therapy - OBSERVATIONAL ONLY; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: medical chart review; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: assessment of therapy complications; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Compare Efficacy and Safety Between Quetiapine and Haloperidol in Treatment Delirium
Brief Summary: The purpose of this study is to determine whether quetiapine, and haloperidol are effective and safe in the treatment psychiatric symptoms in patients with delirium.


Options:
A: Arm Label: A - placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ziprasidone | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): C | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): A - placebo
B: Arm Label: quetiapine; Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Arm Label: haloperidol; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidol | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): quetiapine | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): haloperidol
C: Arm Label: Dexmedetomidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Saline placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Saline placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidol | Intervention Type: DRUG; Name: dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Intervention Trial for Smoking Cessation With Intensive Advice in Diabetic Patients in Primary Health Care
Brief Summary: This study addresses an important problem in public health, smoking in diabetics. The morbidity and mortality observed in diabetics is linked to macro and microvascular problems. The consumption of tobacco has a multiplying effect on these vascular problems in diabetics. This study aims to evaluate the effectiveness of an intensive intervention in tobacco addiction in diabetic patients in primary care.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Smoking cessation program; Type: EXPERIMENTAL; Interventions: Other: Smoking cessation program | Intervention Type: OTHER; Name: Smoking cessation program; Assigned to Arm(s): Smoking cessation program
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Counseling | Intervention Type: BEHAVIORAL; Name: Lifestyle Counseling; Assigned to Arm(s): Lifestyle Counseling
C: Arm Label: Standard support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support | Arm Label: Proactive telephone support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support | Arm Label: Standard support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Arm Label: Proactive support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Intervention Type: BEHAVIORAL; Name: Proactive telephone support; Assigned to Arm(s): Proactive support & offer NRT, Proactive telephone support | Intervention Type: BEHAVIORAL; Name: Reactive (standard) telephone support; Assigned to Arm(s): Standard support, Standard support & offer NRT | Intervention Type: DRUG; Name: Offer of voucher for cost-free Nicotine Replacement Therapy; Assigned to Arm(s): Proactive support & offer NRT, Standard support & offer NRT
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Varenicline plus Motivational Interviewing counseling | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Varenicline without counseling | Intervention Type: OTHER; Name: Varenicline plus Motivational Interviewing counseling; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Varenicline without counseling; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of SIS Mesh for Anterior Repair: A Pilot Study
Brief Summary: Prolapse occurs when pelvic organs drop down and cause a bulging of the tissues. An "anterior wall prolapse" occurs when the front of the vagina loses its support, and the bladder drops down and rotates into the vaginal opening. The bladder can cause a bulge out of the vagina.

One of the treatment options available is to repair the anterior wall surgically. The goals of surgery are to return the anatomy to its usual position, ensuring that all the pelvic floor organs (bladder, vagina and rectum) can function properly. The ideal surgical repair would also be long lasting.

Two surgical options are routinely performed in Calgary for repair of an anterior compartment prolapse. One option involves fixing the organs back in place using sutures. The other option uses sutures plus a mesh made of small intestine submucosa (SIS) that is already licensed for use in Canada. The SIS mesh is slowly absorbed after it is placed in the pelvic area. The investigators do not know which of these two options is the best surgical procedure. Both may have different advantages that would result in better results. This study is designed to try and find out if one of these procedures is better, and if a larger study may be needed.


Options:
A: Intervention Type: DEVICE; Name: Low-weight prolypropylene mesh; Assigned to Arm(s): N/A
B: N/A
C: Arm Label: Anterior Colporrhaphy (sutured repair); Type: PLACEBO_COMPARATOR; Interventions: Procedure: sutured anterior vaginal prolapse repair | Arm Label: Perigee (grafted repair); Type: ACTIVE_COMPARATOR; Interventions: Device: grafted anterior prolapse repair | Intervention Type: DEVICE; Name: grafted anterior prolapse repair; Assigned to Arm(s): Perigee (grafted repair) | Intervention Type: PROCEDURE; Name: sutured anterior vaginal prolapse repair; Assigned to Arm(s): Anterior Colporrhaphy (sutured repair)
D: Arm Label: SIS Mesh (Cook Medical); Type: EXPERIMENTAL; Interventions: Device: SIS mesh (Cook Medical), Procedure: Anterior prolapse repair | Arm Label: No-mesh; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Anterior prolapse repair | Intervention Type: DEVICE; Name: SIS mesh (Cook Medical); Assigned to Arm(s): SIS Mesh (Cook Medical) | Intervention Type: PROCEDURE; Name: Anterior prolapse repair; Assigned to Arm(s): No-mesh, SIS Mesh (Cook Medical)

Answer: D